Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

17.39 +0.40 (+2.35%)
Streaming Delayed Price Updated: 12:53 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Is Flex (FLEX) Stock Moving Today? ↗
Flex stock is on the move Wednesday after the company completed its spinoff of Nextracker by distributing its stake to holders of its stock. 
Via InvestorPlace
News headline image
Why Is Trinity Place (TPHS) Stock Up 97% Today? ↗
Trinity Place stock is up on Wednesday as investors in TPHS react to a new forbearance agreement update with heavy trading of the shares. 
Via InvestorPlace
News headline image
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? ↗
Dyne Therapeutics stock is rising higher on Wednesday as investors in DYN react to positive clinical trial news from the company. 
Via InvestorPlace
News headline image
Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today? ↗
Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning! 
Via InvestorPlace
News headline image
Why Shares of Dyne Therapeutics Fell This Week ↗
Insiders sold more than 15,000 shares of company stock on Tuesday. 
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition ↗
After dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20. 
Via InvestorPlace
News headline image
Dyne Therapeutics to Present at November Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Dyne Therapeutics ↗
 
Via Benzinga
News headline image
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at October Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Jefferies Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.